Search PubMed⌕ Search

PubMed · 10257553

A portable ECG simulator.

Abstract

A simple and low cost ECG simulator is described. The output waveform is a narrow pulse followed by a T-wave which extends to about one-half of the period. This waveform is acceptable by the medical staff and provides to the BMET a simple, calibrated waveform. Four switches control the simulator; (1) power on or off; (2) fixed rates of 60 or 120 BPM; (3) filtered or normal; (4) square wave or pulse. The amplitude is calibrated to 1 mv for a three-lead cable and 0.5 mv steps for use with a five-lead cable. An output of 1.8 volts is available for driving auxiliary equipment. An external light-emitting diode provides visual indication in all modes. A push button switch provides manual testing of respiration modules.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L M Walden. A portable ECG simulator.. https://doi.org/10.1097/00004669-198204000-00003

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Clinical experience with routine diode dosimetry for electron beam radiotherapy.

PURPOSE: Electron beam radiotherapy is frequently administered based on clinical setups without formal treatment planning. We felt, therefore, that it was important to monitor electron beam treatments by in vivo dosimetry to prevent errors in treatment delivery. In this study, we present our clinical experience with patient dose verification using electron diodes and quantitatively assess the dose perturbations caused by the diodes during electron beam radiotherapy. METHODS AND MATERIALS: A commercial diode dosimeter was used for the in vivo dose measurements. During patient dosimetry, the patients were set up as usual by the therapists. Before treatment, a diode was placed on the patient's skin surface and secured with hypoallergenic tape. The patient was then treated and the diode response registered and stored in the patient radiotherapy system database via our in-house software. A customized patient in vivo dosimetry report showing patient details, expected and measured dose, and percent difference was then generated and printed for analysis and record keeping. We studied the perturbation of electron beams by diodes using film dosimetry. Beam profiles at the 90% prescription isodose depths were obtained with and without the diode on the beam central axis, for 6-20 MeV electron beams and applicator/insert sizes ranging from a 3-cm diameter circular field to a 25 x 25 cm open field. RESULTS: In vivo dose measurements on 360 patients resulted in the following ranges of deviations from the expected dose at the various anatomic sites: Breast (222 patients) -20.3 to +23.5% (median deviation 0%); Head and Neck (63 patients) -21.5 to +14.8% (median -0.7%); Other sites (75 patients) -17.6 to +18.8% (median +0.5%). Routine diode dosimetry during the first treatment on 360 patients (460 treatment sites) resulted in 11.5% of the measurements outside our acceptable +/-6% dose deviation window. Only 3.7% of the total measurements were outside +/-10% dose deviation. Detailed investigations revealed that the dose discrepancies, overwhelmingly, were due to inaccurate diode orientation and positioning, especially in the regions with rapidly changing contours and/or sloping surfaces. The presence of a diode in the treatment field was found, in some cases, to cause significant dose reduction, most noticeable with smaller fields and lower energy beams. The reduction in dose ranged from 16% (for a 6 MeV beam and a 3 cm diameter circular field) to 4% (for a 12 MeV beam and a 10 x 10 cm field). CONCLUSIONS: Diode dosimetry was found to be convenient and valuable for verifying in real time the dose delivery accuracy of electron beam treatments, but with some caveats. When treating a small field by low energy electrons, frequent use of diodes is undesirable, because it might result in appreciable reduction of dose to the target volume.

Calibration↗

Use of a three-factor interpretive optimisation strategy in the development of an isocratic chromatographic procedure for the screening of diuretics in urine samples using micellar mobile phases.

Screening of diuretics in urine is feasible through direct injection of the samples into the chromatographic system and isocratic reversed-phase liquid chromatography (RPLC) with micellar-organic mobile phases of sodium dodecyl sulfate (SDS) and 1-propanol. The surfactant coverage of the chromatographic column makes the addition of organic competing amines less necessary than in conventional aqueous-organic RPLC to achieve well-shaped peaks. Also, the range of elution strengths of micellar mobile phases required to elute mixtures of hydrophobic and hydrophilic diuretics is smaller. This allows the isocratic separation of the diuretics within adequate analysis times. An interpretive methodology is applied to optimise the resolution of a mixture of 15 diuretics of diverse polarity and acid-base behaviour (althiazide, amiloride, bendroflumethiazide, benzthiazide, bumetanide, canrenoic acid, chlorthalidone, ethacrynic acid, furosemide, piretanide, probenecid, torasemide, triamterene, trichloromethiazide and xipamide), using pH and concentrations of surfactant and organic modifier in the mobile phase as separation factors. Twelve diuretics were resolved in 25 min using 0.055 M SDS-6.0% 1-propanol at pH 3.0. The mixture of 15 diuretics was also resolved with two mobile phases showing complementary behaviour: 0.05 M SDS-5.6% 1-propanol at pH 5.4 and 0.11 M SDS-5.4% 1-propanol at pH 4.2. The results were applied to the analysis of urine samples with limits of detection similar to those usually reported for aqueous-organic RPLC, taking into account that the samples were injected without any previous treatment to separate or preconcentrate the analytes.

Calibration↗